Malarivon (Chloroquine Phosphate)

Chloroquine phosphate accumulates in the parasite’s acidic food‑vacule, where it blocks heme polymerase, preventing detoxification of free heme. The resulting toxic heme buildup kills the malaria parasite. In autoimmune diseases, the drug interferes with antigen processing and cytokine release, dampening abnormal immune activity.

The specific dose of Malarivon is determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and other individual factors. Healthcare providers set the regimen according to current clinical guidelines and patient needs.

Safety data for chloroquine phosphate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and after a thorough discussion with a qualified obstetrician or maternal‑fetal medicine specialist.

To request Malarivon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Malarivon (chloroquine phosphate) belongs to the 4‑aminoquinoline class, offering a long‑standing oral option with a well‑known safety profile. Compared with newer agents such as artemisinin‑based combination therapies, chloroquine is less effective against resistant Plasmodium strains but remains valuable in regions where sensitivity is retained and for its immunomodulatory properties in rheumatologic disease.

Malarivon should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Malarivon is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically directed by a healthcare professional. Dosing intervals and duration are defined by the prescriber according to the therapeutic indication.

The most serious adverse events include retinal toxicity (retinopathy) that can lead to permanent vision loss, cardiac arrhythmias such as QT prolongation, and severe hypoglycemia, especially in patients receiving insulin or sulfonylureas. Regular monitoring and prompt reporting of visual changes or cardiac symptoms are essential.

Malarivon is contraindicated in individuals with known hypersensitivity to chloroquine or related compounds. Patients with pre‑existing retinal disease, significant cardiac conduction abnormalities, or those taking other QT‑prolonging medications should avoid use unless a specialist determines that benefits outweigh risks.